BREAKFAST SESSION - 8:00 – 8:30 am
Perspective on the Evolution of Type 2 Diabetes Management
Learning Objectives:
- Name several recent game-changing developments that have altered the landscape of the management of T2D.
- Define the critical components of holistic T2D management recommended by recent international consensus statements.
- Describe the evolution of incretin-based therapy in the management of T2D.
- Incorporate the latest incretin agents (GLP-1/GIP receptor dual agonists) into practice based on clinical trial evidence and individual patient needs
Speaker
Dr. Ronald Goldenberg, MD, FRCPC, FACE
Consultant Endocrinologist Emeritus
LMC Diabetes & Endocrinology, Vaughan, Ontario, Canada
Dr. Ronald Goldenberg is a consultant endocrinologist emeritus affiliated with LMC Diabetes & Endocrinology in Vaughan, Ontario. He completed his residency in Internal Medicine in 1987 at the University of Toronto, and his fellowship in Endocrinology & Metabolism in 1989 at the University of Toronto. His major areas of interest include clinical care of diabetes, obesity, dyslipidemia and thyroid disorders.
Dr. Goldenberg has been an investigator in a wide array of clinical trials in the areas of diabetes, hypertension, obesity, and dyslipidemia. He has been actively involved in Continuing Medical Education for over 3 decades, with a strong focus on translating evidence-based medicine into practical patient care. Dr. Goldenberg was a councillor on the Diabetes Canada Clinical & Scientific Section Executive Committee from 2010 to 2016. He was a member of the Steering Committee and an author for the 2013 CDA Clinical Practice Guidelines, lead author of the CDA March 2016 Interim Update and co-author of the November 2016 Interim Update on the Pharmacologic Management of Type 2 Diabetes. He was on the Executive Committee and an author for the 2018 Diabetes Canada CPGs.
He was the 2021 recipient of the Diabetes Canada Gerald S. Wong Service Award.